Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia

Acta Haematol. 2004;112(4):217-8. doi: 10.1159/000081276.

Abstract

Interferon (IFN)-alpha is a leukocyte-derived cytokine and is used to treat several hematopoietic malignancies. The most common adverse effects of IFN-alpha are flu-like symptoms and usually insignificant. However, adverse effects due to autoimmune mechanisms are often hazardous and irreversible, although their frequency is low. In the present report, we describe a 55-year-old female with chronic myelogenous leukemia who developed severe autoimmune thrombocytopenia during IFN-alpha therapy. The lowest platelet count was 6 x 10(9)/l with severe hemorrhagic tendency. The present report strongly suggests the clinical importance of autoimmune thrombocytopenia as an adverse effect of IFN-alpha.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Benzamides
  • Female
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Middle Aged
  • Piperazines / therapeutic use
  • Prednisolone / therapeutic use
  • Purpura, Thrombocytopenic, Idiopathic / chemically induced*
  • Pyrimidines / therapeutic use
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Prednisolone